Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

NCT00365599 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: suberoylanilide hydroxamic acid (SAHA, Vorinostat)
DRUG: tamoxifen citrate (Tamoxifen)

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]